ISPC logo

iSpecimen (ISPC) Stock

Profile

Sector:

Healthcare

Country:

United States

IPO:

17 June 2021

Indexes:

Not included

Description:

iSpecimen is a biotechnology company that connects researchers with human biospecimens for medical research. They provide a platform to access and manage biological samples, helping scientists advance studies in areas like drug development and disease understanding, ultimately improving healthcare outcomes.

Events Calendar

Earnings

Next earnings date:

N/A

Recent quarterly earnings:

Aug 04, 2022

Recent annual earnings:

Feb 17, 2022
Dividend

Next ex-dividend date:

N/A

Recent ex-dividend date:

N/A
Splits

Next split:

N/A

Recent split:

Sept 16, 2024

Analyst ratings

Recent major analysts updates

23 Sept '22 EF Hutton
Buy
04 Jan '22 Craig-Hallum
Buy
22 Nov '21 EF Hutton
Buy

Market Data

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Dividend

Profitability

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Efficiency

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Valuation

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Liquidity

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cash Flow

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Institutional Ownership

iSpecimen Will Serve as a Preferred Provider of Cancer Biospecimens
iSpecimen Will Serve as a Preferred Provider of Cancer Biospecimens
iSpecimen Will Serve as a Preferred Provider of Cancer Biospecimens
ISPC
newsfilecorp.com20 December 2024

Woburn, Massachusetts--(Newsfile Corp. - December 20, 2024) - iSpecimen Inc. (NASDAQ: ISPC), a leading online marketplace for human biospecimens, today announced its strategic initiatives for 2025, expanding services to procure high demand cancer biospecimens, enhancing its ability to support groundbreaking cancer research worldwide. The demand for cancer tissue continues to grow as cancer remains a significant area of focus in medical research and investment.

iSpecimen Reports Positive Results on Next Day Quote Program for Researchers and Providers
iSpecimen Reports Positive Results on Next Day Quote Program for Researchers and Providers
iSpecimen Reports Positive Results on Next Day Quote Program for Researchers and Providers
ISPC
newsfilecorp.com13 December 2024

Woburn, Massachusetts--(Newsfile Corp. - December 13, 2024) - iSpecimen Inc. (NASDAQ: ISPC) ("iSpecimen" or the "Company"), an online global marketplace that connects scientists requiring biospecimens for medical research with a network of healthcare specimen providers, announced today positive results attributed to its Next Day Quote Program ("NDQ"). This next-day quote service for researchers and providers is tailored to accelerate the biospecimen transaction process and delivers accurate biospecimen sample pricing within 24 hours of receiving the customer request.

iSpecimen Appoints Robert Lim as CEO and Director
iSpecimen Appoints Robert Lim as CEO and Director
iSpecimen Appoints Robert Lim as CEO and Director
ISPC
newsfilecorp.com12 December 2024

Woburn, Massachusetts--(Newsfile Corp. - December 12, 2024) - iSpecimen Inc. (NASDAQ: ISPC) ("iSpecimen" or the "Company"), an online global marketplace that connects scientists requiring biospecimens for medical research with a network of healthcare specimen providers, announced today that it has appointed Robert Lim as CEO and director. Mr. Lim is the principal and co-founder of De Novo Law Corporation, a Vancouver-based law firm specializing in corporate/commercial law and civil litigation.

iSpecimen Named Top Competitor in $4.4 Billion USD Market
iSpecimen Named Top Competitor in $4.4 Billion USD Market
iSpecimen Named Top Competitor in $4.4 Billion USD Market
ISPC
newsfilecorp.com08 November 2024

Biospecimen Market To Exceed $13.5 Billion USD By 2032 Woburn, Massachusetts--(Newsfile Corp. - November 8, 2024) - iSpecimen Inc. (NASDAQ: ISPC) ("iSpecimen" or the "Company"), an online global marketplace that connects scientists requiring biospecimens for medical research with a network of healthcare specimen providers, announced today the addressable Biospecimen contract research services market is attractive and growing. In fact, according to AceInsight Analytic, the market is presently valued at USD 4.4 billion as of 2023 and is predicted to reach USD 13.5 billion by the year 2032, growing at a 13.3% CAGR during the forecast period.

iSpecimen Releases Cancer Biospecimen Offering; Orders Anticipated of Over $9,500,000 Annually
iSpecimen Releases Cancer Biospecimen Offering; Orders Anticipated of Over $9,500,000 Annually
iSpecimen Releases Cancer Biospecimen Offering; Orders Anticipated of Over $9,500,000 Annually
ISPC
globenewswire.com07 November 2024

WOBURN, Mass., Nov. 07, 2024 (GLOBE NEWSWIRE) -- iSpecimen Inc. (Nasdaq: ISPC) (“iSpecimen” or the “Company”), an online global marketplace that connects scientists requiring biospecimens for medical research with a network of healthcare specimen providers, announced today a significant enhancement to its searchable inventory that provides researchers with increased access to a wide array of biospecimens vital to advancing oncology research and treatments.

iSpecimen Announces 1-for-20 Reverse Stock Split
iSpecimen Announces 1-for-20 Reverse Stock Split
iSpecimen Announces 1-for-20 Reverse Stock Split
ISPC
globenewswire.com11 September 2024

WOBURN, Mass., Sept. 11, 2024 (GLOBE NEWSWIRE) -- iSpecimen Inc.  (Nasdaq: ISPC) (“iSpecimen” or the “Company”), an online global marketplace that connects scientists requiring biospecimens for medical research with a network of healthcare specimen providers,  announced today that it will effect a reverse stock split of its issued and outstanding shares of common stock, par value $0.0001 per share, as well as any shares of common stock held by the Company in treasury, at a ratio of 1-for-20. The reverse stock split will become effective at 4:30 p.m. Eastern Time on September 13, 2024, and the Company's common stock will begin trading on a split-adjusted basis when the market opens on September 16, 2024. The Company's common stock will continue to trade on the Nasdaq Capital Market (“Nasdaq”) under the symbol "ISPC." The new CUSIP number for the Company's common stock following the reverse stock split will be 45032V207.

iSpecimen Inc. (ISPC) Q2 2024 Earnings Call Transcript
iSpecimen Inc. (ISPC) Q2 2024 Earnings Call Transcript
iSpecimen Inc. (ISPC) Q2 2024 Earnings Call Transcript
ISPC
seekingalpha.com10 August 2024

iSpecimen Inc. (NASDAQ:ISPC ) Q2 2024 Earnings Conference Call August 6, 2024 8:30 AM ET Company Participants Phil Carlson - IR, KCSA Strategic Communications Tracy Curley - CEO and CFO Leslie Hoyt - VP, Operations Conference Call Participants Matt Hewitt - Craig-Hallum Capital Group Operator Good morning everyone and welcome to the iSpecimen Second Quarter 2024 Earnings Conference Call. At this time, participants are in a listen-only mode.

iSpecimen Reports Second Quarter 2024 Results
iSpecimen Reports Second Quarter 2024 Results
iSpecimen Reports Second Quarter 2024 Results
ISPC
globenewswire.com06 August 2024

Revenue increased 76% year-over-year to approximately $2.86 million Brielan Smiechowski Named SVP of Sales and Business Development LEXINGTON, Mass., Aug. 06, 2024 (GLOBE NEWSWIRE) -- iSpecimen Inc.  (Nasdaq: ISPC) (“iSpecimen” or the “Company”), an online global marketplace that connects scientists requiring biospecimens for medical research with a network of healthcare specimen providers, today reported its financial and operating results for the three and six month periods ended June 30, 2024.

iSpecimen Inc. (ISPC) Q1 2024 Earnings Call Transcript
iSpecimen Inc. (ISPC) Q1 2024 Earnings Call Transcript
iSpecimen Inc. (ISPC) Q1 2024 Earnings Call Transcript
ISPC
Seeking Alpha12 May 2024

iSpecimen Inc. (NASDAQ: ISPC) Q1 2024 Earnings Conference Call on May 7, 2024 at 8:30 AM ET with company representatives including Phil Carlson, Tracy Curley, and Leslie Hoyt. Conference call participants include Matt Hewitt from Craig Hallum Capital. The call is being recorded.

iSpecimen Reschedules Full Year 2023 Earnings Release and Conference Call
iSpecimen Reschedules Full Year 2023 Earnings Release and Conference Call
iSpecimen Reschedules Full Year 2023 Earnings Release and Conference Call
ISPC
GlobeNewsWire12 March 2024

The Company will now report results after the market closes on March 13, 2024 and reschedules conference call to Thursday, March 14, 2024 at 8:30am Eastern The Company will now report results after the market closes on March 13, 2024 and reschedules conference call to Thursday, March 14, 2024 at 8:30am Eastern

  • 1(current)
  • 2
  • 1(current)
  • 2

FAQ

  • What is the primary business of iSpecimen?
  • What is the ticker symbol for iSpecimen?
  • Does iSpecimen pay dividends?
  • What sector is iSpecimen in?
  • What industry is iSpecimen in?
  • What country is iSpecimen based in?
  • When did iSpecimen go public?
  • Is iSpecimen in the S&P 500?
  • Is iSpecimen in the NASDAQ 100?
  • Is iSpecimen in the Dow Jones?
  • When was iSpecimen's last earnings report?
  • When does iSpecimen report earnings?
  • Should I buy iSpecimen stock now?

What is the primary business of iSpecimen?

iSpecimen is a biotechnology company that connects researchers with human biospecimens for medical research. They provide a platform to access and manage biological samples, helping scientists advance studies in areas like drug development and disease understanding, ultimately improving healthcare outcomes.

What is the ticker symbol for iSpecimen?

The ticker symbol for iSpecimen is NASDAQ:ISPC

Does iSpecimen pay dividends?

No, iSpecimen does not pay dividends

What sector is iSpecimen in?

iSpecimen is in the Healthcare sector

What industry is iSpecimen in?

iSpecimen is in the Diagnostics & Research industry

What country is iSpecimen based in?

iSpecimen is headquartered in United States

When did iSpecimen go public?

iSpecimen's initial public offering (IPO) was on 17 June 2021

Is iSpecimen in the S&P 500?

No, iSpecimen is not included in the S&P 500 index

Is iSpecimen in the NASDAQ 100?

No, iSpecimen is not included in the NASDAQ 100 index

Is iSpecimen in the Dow Jones?

No, iSpecimen is not included in the Dow Jones index

When was iSpecimen's last earnings report?

iSpecimen's most recent earnings report was on 4 August 2022

When does iSpecimen report earnings?

The date for iSpecimen's next earnings report has not been announced yet

Should I buy iSpecimen stock now?

As of today, analysts generally recommend a 'Buy' rating. However, it's important to do your own research and consider your financial situation before making any investment decisions